Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dentsply Sirona (XRAY) EBITDA (2016 - 2025)

Dentsply Sirona's EBITDA history spans 17 years, with the latest figure at -$139.0 million for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 72.69% year-over-year to -$139.0 million, compared with a TTM value of -$422.0 million through Dec 2025, up 51.99%, and an annual FY2025 reading of -$422.0 million, up 51.99% over the prior year.
  • EBITDA for Q4 2025 was -$139.0 million at Dentsply Sirona, up from -$218.0 million in the prior quarter.
  • The five-year high for EBITDA was $172.0 million in Q4 2021, with the low at -$1.2 billion in Q3 2022.
  • Average EBITDA over 5 years is -$85.8 million, with a median of $56.5 million recorded in 2024.
  • Year-over-year, EBITDA tumbled 1022.73% in 2022 and then soared 2200.0% in 2024.
  • Tracing XRAY's EBITDA over 5 years: stood at $172.0 million in 2021, then crashed by 62.21% to $65.0 million in 2022, then grew by 12.31% to $73.0 million in 2023, then crashed by 797.26% to -$509.0 million in 2024, then skyrocketed by 72.69% to -$139.0 million in 2025.
  • Per Business Quant, the three most recent readings for XRAY's EBITDA are -$139.0 million (Q4 2025), -$218.0 million (Q3 2025), and -$128.0 million (Q2 2025).